ActivX was a biopharmaceutical company that discovered and developed highly selective, best in class, small molecule drugs for major unmet medical needs. ActivX used its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with a focus on hematology, oncology, metabolic and inflammatory diseases. Our core technology allows identification and development of highly selective drugs, lowering development risk.